ADC Therapeutics (ADCT) Net Cash Flow: 2018-2024
Historic Net Cash Flow for ADC Therapeutics (ADCT) over the last 7 years, with Dec 2024 value amounting to -$27.6 million.
- ADC Therapeutics' Net Cash Flow rose 77.14% to -$32.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$48.0 million, marking a year-over-year increase of 65.67%. This contributed to the annual value of -$27.6 million for FY2024, which is 42.43% up from last year.
- Latest data reveals that ADC Therapeutics reported Net Cash Flow of -$27.6 million as of FY2024, which was up 42.43% from -$48.0 million recorded in FY2023.
- In the past 5 years, ADC Therapeutics' Net Cash Flow ranged from a high of $323.4 million in FY2020 and a low of -$139.9 million during FY2022.
- For the 3-year period, ADC Therapeutics' Net Cash Flow averaged around -$71.9 million, with its median value being -$48.0 million (2023).
- Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 1,437.78% in 2020, then plummeted by 611.63% in 2022.
- Yearly analysis of 5 years shows ADC Therapeutics' Net Cash Flow stood at $323.4 million in 2020, then plummeted by 91.55% to $27.3 million in 2021, then tumbled by 611.63% to -$139.9 million in 2022, then surged by 65.67% to -$48.0 million in 2023, then skyrocketed by 42.43% to -$27.6 million in 2024.